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INTRODUCTION
Quantitative sensory testing (QST) methods are used to
evaluate sensory function for patients with the respective
symptoms and for patients with increased risk of developing
a neurological disease (Shy et al., 2003). Thermal and also
mechanical incentives are used to measure different sensor
thresholds corresponding to different receptors, peripheral
nerve fibre tips and different CNS tracts (Hanson et al.,
2007). If the test result is abnormal, this suggests sensory
tract dysfunction from receptor to sensory cortex (Shy et al.,
2003). However, QST is used to a greater extent to evaluate
dysfunction of small fibres, as large fibre function is possi-
ble to evaluate using standard investigative techniques
(Cruccu et al., 2009). Based on studies, QST can be used in
cases of diabetic neuropathy, small fibre neuropathy, toxic
neuropathy, uremic neuropathy and different neuropathic
pain syndromes (Shy et al., 2003). The latest studies show
that QST can likely be used for prediction of response to
treatment (Gustorff et al., 2013). However, according to
QST results, it is not possible to determine the level of dys-
function (peripheral or central nervous system), and there-
fore in all cases QST data should be interpreted together
with the clinical picture and another diagnostic tests (EMG,
nerve or skin biopsy, CT, MRI ect.) (Shy et al., 2003). The
German Research Network on Neuropathic Pain developed
standardised QST protocol including 13 parameters for ther-
mal and mechanical pain perception. This protocol allows to
create a complete somatosensory profile for one region in
30 minutes (Rolke et al., 2006). In the present study, we
used 4 of the 13 parameters of thermal QST in analysis of
thinly myelinated A delta fibres, nonmylinated C fibres and
the spinothalamic pathway (Rolke et al., 2006; Gruccu et
al., 2009).
Fibromyalgia (FM) is a chronic disorder manifested by dif-
fuse musculoskeletal pain and additional somatic symptoms
like fatigue, sleep, emotional disturbance, depression, cog-
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Fibromyalgia (FM) is a chronic disorder manifested by diffuse musculoskeletal pain, fatigue,
sleep, and emotional disturbance. The disorder is probably associated with dysfunction of C and
A delta peripheral nerve fibres. Thermal quantitative sensory testing (QST) was used to analyse
thinly myelinated A delta fibres and nonmylinated C fibres, which function in the nociceptive sen-
sory system, and the spinothalamic pathway. The observation that FM pain has neuropathic na-
ture increased the value of QST as an additional diagnostic tool. The research group included 51
patients. Somatic symptoms were assessed using the Fatigue Severity Score (FSS), Fibromyal-
gia Impact Questionnaire (FIQ) and American College of Rheumatology (ACR) 2010 year diag-
nostic criteria. QST was performed by using thermal stimulus at wrist and feet. QST results were
compared with 20 non-FM controls matched for age and sex. FM patients showed significant al-
teration of thermal perception and pain threshold compared with that in healthy controls, which
demonstrated possible neuropathic pain nature in FM patients. Changes were more expressed in
warm perception and heat pain threshold, which probably indicates that in FM patients C fibres
are more damaged and warm perception and warm pain threshold are more sensitive, which may
be used as FM diagnostics. We also found statistically significant negative correlations between
warm and cold perception thresholds and between heat and cold pain thresholds, reflecting cen-
tral sensitization or a defective pain inhibitory system.
Key words: quantitative sensory testing, fibromyalgia, pain.
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nitive symptoms, gastrointestinal symptoms, and headache.
FM has significant negative impact on a patient’s daily
functioning and leads to disability and poor quality of life
(Lucas et al., 2006; Sommer, 2010; Wolfe et al., 2010). In
one study, FM prevalence was determined to be between
2.0% and 4.7% (Branco et al., 2008) and in another, be-
tween 0.7% and 3.3% (Sommer, 2010). Disorder is more
common in the middle age. Females have FM 8 times more
frequently than males (Albin et al., 2008). Diagnosis is clin-
ical and is based on the 1990 American College of
Rheumatology (ACR) diagnostic criteria (Hakim et al.,
2010). According to these criteria, FM diagnosis can be es-
tablished, if a patient has chronic widespread pain and on
physical examination 11 or more of a possible 18 tender
points are positive. A tender point can be considered as pos-
itive if an individual reports pain when a region is palpated
with 4 kg of pressure. Chronic widespread pain is defined
by diffuse musculoskeletal pain that is present daily three
months or more, in sites on both sides of the body, both
above and below the waist, as well as in the spinal region.
Other possible reasons for pain need to be excluded (Hakim
et al., 2010; McCarberg and Clow, 2009).
In 2010, ACR presented new FM diagnostic criteria, which
include somatic symptom assessment, and these criteria can
be easily used in primary care. The new criteria also consid-
er FM diagnosis, when somatic symptoms are widely pre-
sented and are more expressed than pain (Wolfe et al.,
2010).
Despite the fact that FM etiology and pathogenesis remains
unclear (Albin et al., 2008), studies suggest that FM pain
has neuropathic nature (Dworkin and Fields, 2005; Marti-
nez-Livan, 2012). Previous studies have shown reduction in
dermal unmyelinated nerve fibre bundles in skin samples of
patients with FM, compared with that in control groups,
whereas myelinated nerve fibres were not affected (Uceyler
et al., 2013). Structural and functional imaging studies of
the central nervous system have led to the concept that FM
is a disorder of central sensitisation or a defective pain in-
hibitory system (Sommer, 2010).
The observation that FM pain has neuropathic nature in-
creases the value of QST as an additional diagnostic tool.
Previous studies showed the difference of thermal QST re-
sults between FM patients and a control group, but the re-
sults differ (Klauenberg et al., 2008; Plauf et al., 2009;
Pavlakovic and Petzke, 2010; Blumenstiel et al., 2011;
Tampina et al., 2012; da Silva et al., 2013; Uceyler et al.,
2013).
The aim of the study was to identify changes in thermal per-
ception and pain threshold of FM patients in correlation
with clinical symptoms.
MATERIALS AND METHODS
Population. The research group included 51 patients under-
going treatment in the outpatient clinic of Pauls Stradiòð
Clinical University Hospital. All patients gave written con-
sent for participation in the study. The Rîga Stradiòð
University Ethics Committee gave permission for the study.
The FM diagnosis was based on ACR diagnostic criteria of
1990 (McCarberg, 2009; Hakim, 2010).
Exclusion criteria were previously known polyneuropathy,
diabetes mellitus, and lumbar or cervical radiculopathy
clinical symptoms.
Of the 51 patients included in the study 50 were female, and
1 was male. Average age was 51.71 years (min – 24 years,
max – 72 years, SD ± 10.31). Average duration of symp-
toms was 7.97 years (min – 0.5 year, max – 30 years, SD ±
11.98). Average age of disease at onset was 43.73 years
(min – 12 years, max – 70 years, SD ± 11.98).
Before observation, 10 (19.61%) patients had not received
prior medical treatment, and 33 (64.7%) patients had re-
ceived combined therapy with at least two medications.
Antidepressants were most frequently used in therapy; they
were received by 28 (54.9%) patients of 51 patients in-
cluded in the study. In 24 (47.06%) cases, anticonvulsant
therapy was used, 17 (33.33%) patients received muscle re-
laxants, 5 (9.80%) patients — atypical neuroleptics, 5
(9.80%) patients — opioid analgesics, 6 (11.76%) patients
— benzodiazepine, 2 (3.92%) patients — nonselective beta
blockers, and 18 (35.29%) patients — antipyretic analge-
sics.
Symptom assessment. To evaluate pain and somatic symp-
toms and influence of disorders on the quality of life, pa-
tients were interviewed using several questionnaires.
Forty-one patients were examined with 2010 ACR diagnos-
tic criteria for FM. The questionnaire consisted of two parts:
1) widespread pain index and 2) symptom severity score to
evaluate patient fatigue, cognitive symptoms and other pos-
sible somatic symptoms. The maximal score in first part
was 19 and in the second part — 12. FM diagnosis is con-
siderable if the score in first part is equal or more than 7 and
in the second part equal or more than 5, or if score in the
first part is from 3 till 6 and in the second part equal to or
more than 9 (Wolfe et al., 2010).
All patients were interviewed to determine the Fatigue Se-
verity Scale (FSS). The maximal score was 63. The score of
36 or more indicates chronic fatigue (Lauren, 2015).
To estimate FM influence on quality of life, we used the Fi-
bromyalgia Impact Questionnaire (FIQ) for all patients. The
maximal score is 100. A score of 50 corresponds to the av-
erage rating for patients with FM, and a score above 70 in-
dicates severe course of disease (Bennett, 2005; Assumpa-
cao et al., 2010).
Quantitative sensory testing. Forty-nine patients were
tested using thermal QST.
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A Medoc Pathway device (TSA-II, Medoc, Israel) for esti-
mation of thermal QST. The device generates a defined and
calibrated impulse within certain limits allowing to evaluate
small nerve fibre (A_ and C) function (Anonymous, 2009;
Cruccu et al., 2009). During the test, a probe that warmed or
cooled patient’s skin was attached to the skin of the patient.
Starting with an adapting temperature (32 °C), the probe
generated a calibrated thermal stimulus, depending on the
test method. In the current study we used the limits method,
by which the temperature of the stimulus continuously in-
creased or decreased. The patient stops the increase or de-
crease of the stimulus when a predefined sensation is per-
ceived. The temperature during the test can rise up to +50
°C and fall to +20 °C. If the maximal or minimal tempera-
ture limit is reached, the device stops and returns to the
adapting temperature. During the test, the patient cannot see
the screen (Rolke et al., 2006; Anonymous, 2009). The used
method allows to estimate warm and cold hypoesthesia,
hyperesthesia (allodynia) and heat hypoalgesia. Warm and
cold perception thresholds were determined four times each
in course; cold and heat pain perception thresholds were de-
termined three times each in course. Patients were tested on
wrist and foot dorsal surfaces.
To compare a single patient’s QST data with the group
mean of age and gender matched healthy controls (HC), the
data were Z-transformed for each parameter as follows: Z-
score = (Mean single patient – Mean controls)/SD controls.
A Z-score value higher than 1.95 and lower than –1.95 indi-
cated significant differences in threshold compared to that
of the control group. A Z-score of zero represented a value
corresponding to the group mean of the HC subjects (Plauf
et al., 2009).
RESULTS
Symptom assessment. Among patients tested using 2010
ACR diagnostic criteria for FM (41 in total), in 40
(97.50%), in 2 (4.88%) patients confirmed with FM, so-
matic symptoms were expressed more than pain. In one pa-
tient, FM diagnosis by 2010 ACR diagnostic criteria was
not confirmed, likely due to clinical improvement.
The estimated mean widespread pain index in the patients
was 12.15 (min – 3, max – 18, SD ± 3.99) (p < 0.0001).
More frequent areas of pain were lower and upper parts of
the back (90%) and shoulders (89%). More than 70% of pa-
tients reported pain in their legs, and more than 60% in
arms (Fig. 1).
The mean symptom severity score was 8.15 (min – 4, max –
11, SD ± 1.62) (p < 0.0001). Data on somatic symptom fre-
quency and severity are shown in Tables 1 and 2.
Fig. 1. Frequency of painful regions in FM patients (assessed by 2010
ACR diagnostic criteria).
T a b l e 1
SOMATIC SYMPTOM SEVERITY ASSESSED BY 2010 ACR DIAG-





No symptoms 0 4 (9.76%)
Slight or mild problems;
generally mild or intermittent
0 16 (39.02%) 15 (36.59%)
Moderate; considerable
problems; often present
and/or at a moderate level
20 (48.78%) 17 (41.46%) 18 (43.90%)
Severe: pervasive, continu-
ous, life disturbing problems
21 (51.22%) 4 (9.76%) 8 (19.51%)
T a b l e 2
SOMATIC SYMPTOMS FREQUENCY ASSESSED BY 2010 ACR DI-
AGNOSTIC (patient number and percentage of total)
Dry mouth 30 (73.17%) Frequent urination 24 (58.54%)
Pain in upper abdomen 18 (43.90%) Hives/welts 12 (29.27%)
Diarrhea 15 (36.59%) Ringing in ears 30 (73.17%)
Muscle weakness 36 (87.80%) Bladder spasms 11 (26.83%)
Headache 36 (87.80%) Muscle spasms 29 (70.73%)
Hearing difficulties 23 (56.10%) Dry eyes 17 (41.46%)
Raynauld’s 11 (26.83%) Pain/cramps in abdo-
men
18 (43.90%)
Depression 33 (80.49%) Loss of appetite 14 (34,15%)
Constipation 13 (31.71%) Rash 10 (24.39%)
Dizziness 34 (82.93%) Vomiting 6 (14.63%)
Sun sensitivity 19 (46.34%) Hair loss 19 (46.34%)
Nausea 22 (53.66%) Heartburn 22 (53.66%)
Nervousness 36 (87.80%) Fever 25 (60.98%)
Chest pain 20 (48.78%) Numbness/tingling 35 (85.37%)
Remembering problem 37 (90.24%) Blurred vision 31 (75.61%)
Itching 19 (46.34%) Oral ulcers 3 (7.32%)
Insomnia 36 (87.80%) Loss/change in taste 8 (19.51%)
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According to the Fatigue Severity scale, 49 (96%) patients
of 51 had chronic fatigue (p < 0.0001), and two patients had
a score less than 36. The mean score was 53.86 (min – 25,
max – 63, SD ± 8.9) (p < 0.0001).
The FIQ mean score was 64.43 (min – 25.72, max – 95.45
SD ± 15.06) (p < 0.0001). Nine (18%) patients of 51 had a
score less than 50.22 (43%) patients had a score between 50
and 70 and 20 (39%) patients of 51 had a score more than
70, indicating severe course of disease (p < 0.0001).
Quantitative sensory testing. The QST results for FM and
the control group are shown in Table 3 and Figures 2 and 3.
Estimation of perception and pain threshold mean values
from all tested surfaces showed that in the FM group, six
(12%) patients had a cold detection threshold (CDT) less
than 27 °C (min – 20.00 °C, max – 26.15 °C, 23.92 ± 3.04;
mean ± SD), indicating extreme cold hypoesthesia (p <
0.0001). Four (8%) patients had a warm detection threshold
(WDT) above 40 °C (min – 40.73 °C, max – 42.78 °C,
41.79 ± 0.87; mean ± SD), indicating extreme warm hypo-
esthesia (p < 0.0001). Twenty-five (51%) patients had a
heat pain threshold (HPT) above 45 °C (min – 45.10 °C,
max – 49.82 °C, 47.20 ± 1.10; mean ± SD), indicating ex-
treme heat hypoalgesia (p < 0.0001). Two (4%) patients had
a cold pain threshold (CPT) above 27 °C, indicating ex-
treme cold hyperalgesia and two (4%) patients had a HPT
below 40 °C, indicating extreme heat hyperalgesia. In seven
patients (14%), we observed a paradox heat sensation — a
subject experienced cold as hot.
T a b l e 3
RESULTS OF QUANTITATIVE SENSORY TESTING (QST)
FM ( mean ± SD) HC ( mean ± SD)
CDP min – 20.00 °C, max – 31.23 °C (29.00 °C ± 2.37) min – 27.51 °C, max – 31,15 °C (29.76 °C ± 0,86)
WDP min – 33.85 °C, max – 42.78 °C (37.35 °C ± 2.10) min – 33.51 °C, max – 35.87 °C (34.66 °C ± 0,73)
CPT min – 20.00 °C, max – 28.63 °C (22.03 °C ± 2.49) min – 20.00 °C, max – 20.20 °C (20.30 °C ± 0.68)
HPT min – 37.87 °C, max – 49.82 °C (44.92 °C ± 2.71) min – 41.94 °C, max – 45.34 °C (43.69 °C ± 1.06)
Mean threshold difference between legs and arms (mean threshold in legs minus mean threshold in arms)
CDT –1.64 °C
(arms mean – 29.82 °C, legs mean 28.18 °C)
0.62 °C
(arms mean – 29.45 °C, legs mean 30.07 °C)
WDT 3.57 °C
(arms mean – 35.57 °C, legs mean 39.14 °C)
–0.08 °C
(arms mean – 34.7 °C, legs mean 34.62 °C)
CPT 0.06 °C
(arms mean – 22.00 °C, legs mean 22.06 °C)
–0.19 °C
(arms mean – 20.39 °C, legs mean 20.20 °C)
HPT 1.21 °C
(arms mean – 44.31 °C, legs mean 45.52 °C)
–0.32 °C
(arms mean – 43.85 °C, legs mean 43.53 °C)
Right – left side difference 2 °C (patients number in total (patients in percentage of all))
CDT Between arms 6 (12%) 2 (10%)
Between legs 13 (27%) 1 (5%)
WDT Between arms 16 (33%) 3 (15%)
Between legs 24 (49%) 5 (25%)
CPT Between arms 16 (33%) 2 (10%)
Between legs 5 (10%) 2 (10%)
HPT Between arms 15 (31%) 3 (15%)
Between legs 16 (33%) 6 (30%)
CDT, cold detection threshold; WDT, warm detection threshold; CPT, cold pain threshold; HPT, heat pain threshold; FM, fibromyalgia patients; HC, healthy
control
Fig. 2. Cold perception and cold pain thresholds results for FM and HC.
FM, fibromyalgia patients; HC, healthy control
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In the HC group, we did not observe cold hypoesthesia be-
low 27 °C, warm hypoesthesia above 40 °C or cold hyperal-
gesia above 27 °C. Three (15%) patients had heat hypo-
algesia above 45 °C.
Comparing the FM and HC groups, we observed a large
left-right side difference in FM and larger difference in
threshold between arms and feet. Forty-five (92%) of FM
patients had a left-right side difference more than 2 °C at
least in one modality, while in the in HC group, 15 (75%)
patients showed a left-right side difference more than 2 °C
at least in one modality.
According to z-scores mean values for comparison to the
control group, 69% of all patients had loss of warm sensa-
tion (warm hypoesthesia), which was more prominent in
feet (63% of all patients) than in arms (18% of all patients).
Forty-seven percent of all patients had loss of heat pain sen-
sation (heat hypoalgesia), also more prominent in feet (37%
of all patients) than in arms (29% of all patients). Twenty-
two percent of all patients had loss of cold sensation (cold
hypoesthesia), in feet — 27% of all patients, in arm — 6%
of all patients. Fourteen percent of all patients had increased
heat pain sensation (heat hyperalgesia), which was more
prominent in arms (18% of all patients) than in foot (4% of
all patients). Forty-one percent of all patients had increased
cold pain sensation, compared to the control group (cold hy-
peralgesia), without a significant difference between feet
and arms. Z-scores results of thermal quantitative sensory
testing are presented in Figures 4–7.
Correlations. There was found statistically significant (p <
0.01) moderate negative correlation (r = -0.553) between
cold perception threshold and warm perception threshold
(Fig. 8) and statistically significant (p < 0.01) moderate
negative correlation (r = -0.535) between cold pain thresh-
old and heat pain threshold (Fig. 9). We also found a sig-
nificant (p < 0.01) moderate positive correlation (r = 0.415)
between the FIQ and the FSS scores (Fig. 10).
DISCUSSION
This study described clinical characteristics of FM patients
and demonstrated significant differences in thermal QST
parameters between FM and HC groups. The QST results of
FM patients in all modalities were more variable than in the
Fig. 3. Warm perception and heat pain thresholds results for FM and HC.
FM, fibromyalgia patients; HC, healthy control
Fig. 4. Cold perception threshold z-score.
Fig. 5. Warm perception threshold z-score.
Fig. 6. Cold pain threshold z-score.
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HC group. However, thermal sensory profiles of the FM
group were predominantly characterized by loss of function
(hypoesthesia, hypoalgesia) in warm and heat pain sensa-
tion, which was more pronounced in foot than in arms.
Some patients showed also loss of cold sensation, mostly in
feet. Cold pain sensation characterized by gain sensation
(hyperalgesia) occurred in similar proportions in arms and
feet. Also, 14% of patients had increased heat pain sensa-
tion, mostly in arms. Many previous studies have shown
significant differences in thermal QST compared with a
control group, but the results differ: some studies reported
increased thermal sensitivity in FM patients, while others
found decreased thermal sensitivity in FM patients com-
pared with that in the control group (Klauenberg et al.,
2008; Plauf et al., 2009; Pavlakovic and Petzke, 2010;
Blumenstiel et al., 2011; Tampina et al., 2012; da Silva et
al., 2013; Uceyler et al., 2013). This suggests heterogeneity
of FM and the possible existence of different subgroups
(Tampina et al., 2012). For warm perception, C fibres are
responsible for deep and burning pain, and A delta fibres for
cold sensation and sharp pain (Lauria, 2005). In our study
we found that warm perception and heat pain threshold are
more impaired and are more significantly different from
control group, comparing with cold perception and cold
pain threshold. This might indicate that in FM patients, C
fibres are more damaged, and that warm perception and
warm pain thresholds are more sensitive modalities for use
as a FM diagnostic.
Based on the German Research Network of Neuropathic
Pain (DFNS) standardized protocol for QST, all QST pa-
rameters are region specific, and there is no significant left
– right side difference (Rolke et al., 2006). In our study we
found that there was no significant difference in cold and
heat perception and pain threshold between feet and hands
in HC, but there was a significant difference in warm per-
ception threshold, heat pain threshold and cold perception
threshold in FM patients. On feet, warm perception thresh-
old and heat pain threshold were higher than the threshold
on hands, while the cold perception threshold was lower.
Cold pain thresholds on hands and feet in FM were similar.
We also found that FM patients, compared with the HC
group, had a more frequent left – right side difference
greater than 2 °C. This finding indicates sensory function
impairment in FM patients. Previous studies also showed
similar results (Klauenberg et al., 2008).
We clinically examined patients using the 1990 ACR diag-
nostic criteria, and also 80% of patients were examined us-
ing the 2010 ACR diagnostic criteria. According to the
1990 ACR FM diagnostic criteria, 12 of 18 points are local-
ised on the upper part of the body (shoulders, neck, upper
back) and arms (Hakim et al., 2010), but in our study we
found that more patients had pain in their legs (73% had
Fig. 7. Heat pain threshold z-score.
Fig. 8. Correlation between warm perception thresholds and cold percep-
tion thresholds.
Fig. 9. Correlation between cold pain thresholds and heat pain thresholds.
Fig. 10. Correlation between FSS and FIQ scores.
FSS, Fatigue Severity Scale; FIQ, Fibromyalgia Impact Questionnaire
220 Proc. Latvian Acad. Sci., Section B, Vol. 69 (2015), No. 5.
pain in their lower leg, 79% — in the upper leg) than in
arms (63% had pain in the lower arm and 67% in the upper
arm, 51% — in the neck). This finding can also explain the
more significant differences in pain and perception thresh-
olds in feet compared with hands. We also found that FM
patients had a high level of fatigue (based on the Fatigue
Severity Scale and 2010 ACR diagnostic criteria for FM).
This finding is consistent with previous studies indicating
that 20 to 70% of FM patients showed Chronic Fatigue syn-
drome according to diagnostic criteria and in the reverse di-
rection, 35 to 70% patients with Chronic Fatigue syndrome
also had positive FM diagnostic criteria (Aaron et al.,
2000). The present study also showed that FM patients have
many other somatic symptoms like: cognitive disturbance,
insomnia, depression, etc. (based on 2010 ACR diagnostic
criteria for FM). The 1990 ACR diagnostic criteria do not
include assessment of somatic symptoms, and thus are in-
complete and have limited use (Wolfe et al., 2010).
We found statistically significant linear correlation between
warm and cold perception thresholds and also between cold
and heat pain thresholds, what suggests that in FM, both A
delta and C nerve fibres are impaired or indicates central
sensitization or defective pain inhibitory system (Sommer,
2010).
No statistically significant linear correlations between QST
results and clinical symptoms were found. Similar results
were obtained also in other studies (Desmeules et al., 2003).
This possibly occurred because QST results or question-
naires results were modified by medication, as some pa-
tients continued its use at the time of examination, or possi-
bly, patients were tested on feet and hand dorsal surface, but
not in the most painful area.
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TERMÂLA KVANTITATÎVA SENSORA TESTÇÐANA FIBROMIALÌIJAS PACIENTIEM
Fibromialìija (FM) ir hroniska slimîba, kas izpauþas ar difûzâm muskuloskeletâlâm sâpçm, nogurumu, miega un emocionâliem
traucçjumiem. Slimîba, iespçjams, ir saistîta ar A delta un C nervu ðíiedru disfunkciju. Termâla kvantitatîva sensora testçðana (QST)
analizç mazmielinizçtas A delta nervu ðíiedras un nemielinizçtas C nervu ðíiedras, kas atbild par nociceptîvo sensoru sistçmu un
spinotalâmisko ceïu. Pieòemot, ka FM sâpçm ir neiropâtisks raksturs, pieaug arî QST vçrtîba kâ papildus diagnostiskam testam. Pçtîjumâ
tika iekïauts 51 pacients. Slimîbas simptomi tika objektivizçti, izmantojot Noguruma smaguma skalu (Fatigue Severity Scale),
Fibromialìijas ietekmes anketu (Fibromialgia Impact Questionnaire) un 2010. gada American College of Rheumatology (ACR) FM
diagnostiskos kritçrijus. QST tika veikta ar termâlo stimulu pçdu un plaukstu dorsâlajâs virsmâs. QST rezultâti tika salîdzinâti ar 20
atbilstoða vecuma un dzimuma kontroles grupas pacientiem. FM pacientiem tika konstatçta ievçrojama aukstuma un siltuma percepcijas un
sâpju sliekðòu atðíirîba, salîdzinot ar kontroles grupas pacientiem, un tas norâda uz neiropâtisko sâpju raksturu FM pacientiem. Izmaiòas ir
vairâk izteiktas siltuma percepcijas un karstuma sâpju sliekðòos. Iespçjams, tas liecina, ka FM pacientiem C ðíiedras ir vairâk skartas un
siltuma percepcijas un karstuma sâpju sliekðòi ir jûtîgâkas modalitâtes, ko var izmantot FM diagnostikâ. Tika arî atklâtas statistiski ticamas
negatîvas korelâcijas starp siltuma un aukstuma percepcijas sliekðòiem un starp karstuma un aukstuma sâpju sliekðòiem, kas var norâdît uz
centrâlo sensibilizâciju vai defektîvo sâpju inhibçjoðu sistçmu FM pacientiem.
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